CART Medical

What CART Medical does

CART Medical (Nanjing Kati Medical Technology Co., Ltd., 南京卡提医学科技有限公司) is a clinical-stage Chinese biotech founded in 2017 in Nanjing, China, developing CAR-T cell therapies for malignant solid tumors. The company was founded by Dr. Wang Enxiu, a former core member of Dr. Carl June's CAR-T development team at the University of Pennsylvania, and is led by a team drawn from top institutions including the Chinese Academy of Sciences, Tsinghua Union Medical College, Nanjing Medical University, and MD Anderson Cancer Center. The company employs 51-100 people and operates from Nanjing Biomedical Valley in Jiangbei New District.

CART Medical's core technology is the proprietary DAP-CAR platform, which uses DAP12 to replace CD3zeta in the CAR architecture, providing natural immune receptor signals and separating recognition from activation domains. This design is engineered to maintain CAR expression and T cell function within the immunosuppressive solid tumor microenvironment — a key limitation of conventional CAR-T therapies. The platform has generated five technology variants: DAP-CAR-T (tumor microenvironment resistance), secretory CAR-T (anti-exhaustion), VIVO CAR (low-cost rapid manufacturing), TCR-like CAR-T (panoramic activation without HLA matching), and dual-epitope dual-targeting CAR-T. The company has filed 38 domestic and international patent applications, with granted patents in the US, Europe, and China. Pipeline candidates include KT032 (MSLN CAR-T, NMPA IND-approved September 2023 for advanced ovarian cancer), KT127 (TCR-like CAR-T, in clinical trials for ovarian cancer), GD2-CART (pediatric neuroblastoma), and multiple additional candidates (KT030, KT095, KT081, KT051) targeting ovarian, pancreatic, mesothelioma, sarcoma, and neuroblastoma indications.

CART Medical's business model is currently pre-revenue: the company generates no commercial product revenue and provides all treatments free of charge to patients enrolled in clinical trials. Revenue is exclusively sourced from R&D-stage equity financing, with the most recent disclosed round being a 70 million RMB Series A+ in February 2022 at a 350 million RMB post-money valuation. Future revenue mechanics are expected to derive from commercialization of approved CAR-T products (one-time license/sale model) and potential milestone payments from strategic partners. The go-to-market is currently sales-led through investigator-initiated trials (IIT) and registered clinical trials at four domestic hospital partners in Jiangsu Province, supplemented by conference participation and scientific publication for industry positioning. The company has not yet defined commercial pricing.

Name

CART Medical

Legal name

南京卡提医学科技有限公司

Website

https://cart-med.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

CART Medical is a clinical-stage Chinese biotech developing proprietary DAP-CAR-T cell therapies for solid tumors including ovarian cancer, pancreatic cancer, and neuroblastoma. Founded in 2017 in Nanjing, the company is pre-revenue and currently advancing pipeline candidates through NMPA clinical trials.

Ownership category

akta.pro rank

Product category

CAR-T Cell Therapy (Solid Tumor Biologics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• CAR-T cell therapy
• Solid tumor immunotherapy
• Cell therapy drug development
• DAP-CAR platform
• Chimeric antigen receptor therapy

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. CAR-T Cell Therapy Development and Commercialization: The company is in clinical-stage development of novel CAR-T cell drugs for solid tumors. Revenue will be generated from future product commercialization following regulatory approval. Currently all clinical treatments are provided at no cost to patients in clinical trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

CART Medical is a clinical-stage biopharmaceutical company developing novel CAR-T cell therapy drug candidates for malignant solid tumors. It leverages its proprietary DAP-CAR signaling platform—which replaces CD3ζ with DAP12 and separates recognition from activation domains—to overcome T cell exhaustion in the tumor microenvironment. The company currently has multiple pipeline candidates (KT032, KT127, GD2-CART, KT095, among others) in IIT and registered clinical trials in China, with all treatments currently provided at no cost to patients in clinical settings.

Product overview

Nanjing KATI Medical (南京卡提医学科技有限公司) is a clinical-stage innovative cell drug company developing novel CAR-T cell therapies for malignant solid tumors. Founded in 2017 by Dr. Enxiu Wang, a core member of the Carl June team at the University of Pennsylvania. The company has built four major product matrices around solid tumor cell therapy: 'Identification, Activation, Carrier, and Process,' encompassing multiple CAR-T pipelines. The core portfolio includes: KT032细胞注射液 (MSLN-targeting CAR-T for advanced ovarian cancer, NMPA IND approved in September 2023), KT127 TCR-like CAR-T细胞注射液 (panoramic-activated for ovarian cancer), GD2-CART (pediatric neuroblastoma), and multiple additional pipeline candidates (KT030, KT095, KT081, KT051). The company's proprietary technology platforms include the DAP-CAR platform (using DAP12 instead of CD3ζ for flexible, tumor microenvironment-resistant activation) and the immune receptor library technology platform. All pipeline candidates are currently in clinical or preclinical stages, with the company operating GMP-compliant manufacturing and quality control facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• KT032 Cell Injection (KT032细胞注射液) A novel multi-chain CAR-T cell injection targeting mesothelin (MSLN), designed for advanced ovarian cancer. Based on the DAP-CAR platform, it uses a parallel signal design to enable flexible T cell activation, allowing CAR-T cells to resist the solid tumor microenvironment and avoid exhaustion. Received NMPA IND implicit approval in September 2023 and is the company's leading pipeline product.
• KT127 TCR-like CAR-T Cell Injection (KT127 TCR-like CAR-T细胞注射液) A panoramic-activated TCR-like CAR-T cell injection targeting mesothelin-positive advanced ovarian cancer. Features a U-shaped design with flexible activation, low side effects, and high durability, leveraging the full T cell activation signaling cascade without requiring HLA matching. Clinical trial launched at Zhongda Hospital of Southeast University in July 2023.
• GD2-CART Cell Injection (GD2-CART细胞注射液) A CAR-T cell injection targeting the GD2 antigen for the treatment of childhood neuroblastoma. Class 1.1 new drug developed by Nanjing KATI for pediatric solid tumors, with clinical research conducted in partnership with Nanjing Children's Hospital (clinical trial initiation meeting held November 2020).
• KT095 (DAP12-based CAR-T for sarcoma) A DAP12-based CAR-T pipeline candidate (KT095) developed using parallel design with DAP12 replacing CD3ζ, being studied for sarcoma treatment. IIT study initiated at Lianyungang First People's Hospital in February 2023.
• KT030 / KT081 / KT051 Pipeline Candidates Additional CAR-T pipeline candidates (KT030, KT081, KT051) developed by KATI as part of the four major product matrices ("Identification, Activation, Carrier, Process") for solid tumor treatment. Various stages of preclinical and clinical development.

Quantifiable outcome

• In 8 MSLN-positive solid tumor patients (7 ovarian cancer, 1 pancreatic cancer): ORR 57.5% (PR 4/7), DCR 100% (SD 3/7), median PFS 7 months, longest PFS 17 months, median OS 11.625 months, longest OS 17 months
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• 诺纳生物 (Nora Bio, a wholly-owned subsidiary of Harbour BioMed, stock code: 02142.HK)coreStrategic or Co-development Partner · 8 August 2023Long-term multi-faceted research collaboration. Nora Bio will provide fully human antibody sequences using its proprietary Harbour Mice platform to support development of next-generation fully human CAR-T cell drugs. The partnership combines CART Medical's CAR signaling platform with Nora Bio's antibody discovery platform.
• 南京德泰生物工程有限公司 (Nanjing Detaib Bioengineering Co., Ltd.)coreTechnology or Integration · 8 July 2023Strategic partnership using Detaib Bio's Single® rapid monoclonal antibody discovery platform to accelerate CAR-T product optimization and efficacy in solid tumor clinical applications. The platform supports multi-species antibody discovery including mice, rabbits, and alpacas with significantly shortened discovery timelines.
• 深圳莱芒生物科技有限公司 (Leman Biotech Co., Ltd.)coreStrategic or Co-development Partner · 4 July 2023Strategic cooperation to explore the application of Meta 10 immunometabolic reprogramming technology in solid tumor CAR-T therapy. Leman Biotech, founded by Dr. Guo Yugang from EPFL, has developed Meta 10 technology that reactivates terminally exhausted T cells. The partnership aims to combine Meta 10 with CART Medical's CAR-T platform for enhanced solid tumor treatment.
• 博腾股份 (Porton Co., Ltd.)coreStrategic or Co-development Partner · 1 January 2023Porton and its subsidiary Porton Biologics are strategic partners supporting CART Medical's lead pipeline commercialization. Porton's chairman and management visited CART Medical in 2023 to discuss cooperation. Porton will provide support for commercial manufacturing of CART Medical's first product.
• 和元生物 (Heyuan Biologics)minorStrategic or Co-development Partner · 1 January 2023Heyuan Biologics' general manager Dr. Jia Guodong visited CART Medical to exchange views on CAR-T innovation, CMC processes, and industry future. Both companies share common understanding on CAR-T future manufacturing processes and plan deep cooperation in pipeline process development.
• 南京圣和药业股份有限公司 (Nanjing Shenghe Pharmaceutical Co., Ltd.)coreStrategic or Co-development Partner · 15 April 2020CART Medical signed a strategic cooperation agreement with Shenghe Pharmaceutical in April 2020 at Nanjing Jiangbei New District Medical Valley. The partnership aims to leverage complementary strengths to advance tumor immunotherapy technology development. Shenghe Pharmaceutical is a comprehensive pharmaceutical company with research and commercialization capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Gracell Biotechnologies: Clinical-stage Chinese CAR-T company developing autologous and allogeneic CAR-T therapies for both hematologic cancers and solid tumors. Comparable in clinical-stage profile and CAR-T platform focus.
• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR-T cell therapies for solid tumors, including MAGE-A4 and other targets. Highly comparable in solid tumor cell therapy approach and clinical-stage profile, with CART Medical's TCR-like platform addressing similar biology.
• CARsgen Therapeutics: Hong Kong-listed Chinese CAR-T developer with a strong focus on solid tumors (e.g., Claudin18.2, GPC3) and hematologic malignancies. Most direct comparable in terms of Chinese solid tumor CAR-T pipeline strategy.
• PersonGen Biomedicine (Suzhou PersonGen): China-based CAR-T developer focused on solid tumors and hematologic malignancies with multiple investigator-initiated and registered clinical trials. Comparable in pipeline depth and clinical-stage CAR-T approach.
• Juventas Cell Therapy (Original Biosciences): Chinese cell therapy company developing CAR-T and related modalities for solid tumors. Directly comparable as a Chinese clinical-stage solid tumor CAR-T peer with multiple pipeline candidates.
• Tessa Therapeutics: Clinical-stage cell therapy company developing autologous CAR-T and TCR-T therapies for solid tumors and hematologic malignancies. Comparable in solid tumor CAR-T pipeline focus and clinical-stage profile.
• Allogene Therapeutics: Clinical-stage biotech pioneering allogeneic (off-the-shelf) CAR-T therapies across both hematologic and solid tumor indications. Comparable as a cell therapy platform player pursuing next-generation engineered T-cell approaches.

Emerging players

• Iovance Biotherapeutics: Commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Comparable as a solid tumor cell therapy company, though using TIL rather than CAR-T technology.

Broad incumbents

• Legend Biotech: Global CAR-T leader (BCMA-targeting Carvykti with Johnson & Johnson). Comparable as a Chinese-origin CAR-T company that has reached commercial approval, representing the upper-bound outcome for clinical-stage Chinese CAR-T developers.
• Gilead/Kite (Yescarta franchise): Established commercial CAR-T leader with approved CD19 CAR-T therapies. Comparable as the dominant commercial CAR-T incumbent that defines the regulatory, manufacturing, and competitive benchmarks any emerging CAR-T company must overcome.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/intent/tweet?source=&text=:%20
• Facebookfacebook.com/sharer/sharer.php?u=&t=
• LinkedInlinkedin.com/shareArticle?mini=true&url=&title=&summary=&source=

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CART Medical